Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

1

Revenue 2014

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Surging Trulicity takes sting out of Lilly's arthritis setback

Surging Trulicity takes sting out of Lilly's arthritis setback

a best-in-class treatment compared to Pfizer's blockbuster drug Ibrance (palbociclib) and Novartis' just-approved Kisqali (ribociclib).

New drugs can't keep Novartis sales on the up

New drugs can't keep Novartis sales on the up. Total group sales down 1% despite Cosentyx profit. ... The continued glacial growth of Novartis' heart failure hope Entresto weighed on its first-quarter results as sales declined on generic competition.

Ipsen appoints executive vice president

Prior to joining Ipsen, Lebeaut has held several leadership positions in clinical development and medical affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi and Novartis.

Deal Watch March 2017

Deal Watch March 2017 Deal Watch March 2017. Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up. ... Novartis has received equity in resTORbio and is eligible for milestone and royalty payments on the products.

Roche’s Alecensa beats Xalkori as first-line lung cancer therapy

Roche’s Alecensa beats Xalkori as first-line lung cancer therapy It competes in the second-line setting with Novartis' Zykadia (ceritinib), and later this year could see another rival in the form of Takeda's brigatinib, acquired along with Ariad in ... Last year, Alecensa made sales of 182m Swiss francs ($180m) while

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Novartis
Global revenue 2014
1: Novartis
2: Pfizer
3: Roche
4: Sanofi
5: Merck & Co.
6: Johnson & Johnson
7: GlaxoSmithKline
8: AstraZeneca
9: Gilead Sciences
10: Takeda
11: AbbVie
12: Amgen
13: Teva
14: Lilly
15: Bristol-Myers Squibb
16: Bayer
17: Novo Nordisk
18: Astellas
19: Boehringer Ingelheim
20: Actavis
21: Otsuka
22: Daiichi Sankyo
23: Biogen Idec
24: Baxter
25: Merck KGaA
US revenue 2014
1: Gilead Sciences
2: Johnson & Johnson
3: Pfizer
4: Roche
5: Novartis
6: Amgen
7: Merck & Co.
8: Sanofi
9: AbbVie
10: Actavis
11: AstraZeneca
12: GlaxoSmithKline
13: Lilly
14: Bristol-Myers Squibb
15: Novo Nordisk
Oncology revenue 2014
1: Roche
2: Novartis
3: Celgene
4: Johnson & Johnson
5: Bristol-Myers Squibb
6: Lilly
7: Takeda
8: AstraZeneca
9: Merck & Co.
10: Amgen
11: Pfizer
12: Astellas
13: Bayer
14: Otsuka
15: Sanofi
16: Merck KGaA
17: Eisai
18: AbbVie
19: Pharmacyclics
20: Incyte
Immunology revenue 2014
1: AbbVie
2: Johnson & Johnson
3: Pfizer
4: Amgen
5: Merck & Co.
6: Astellas
7: Roche
8: Novartis
9: Bristol-Myers Squibb
10: Mitsubishi Tanabe
11: UCB
12: Hisamitsu
13: Daiichi Sankyo
14: Takeda
CNS revenue 2014
1: Pfizer
2: Biogen Idec
3: Novartis
4: Otsuka
5: Teva
6: Johnson & Johnson
7: Lilly
8: Merck KGaA
9: AstraZeneca
10: Shire
11: Bristol-Myers Squibb
12: UCB
13: Lundbeck
14: Eisai
15: GlaxoSmithKline
16: Sanofi
17: Mylan
18: Indivior
19: Actavis
20: Bayer
Cardiovascular revenue 2014
1: AstraZeneca
2: Sanofi
3: Merck & Co.
4: Daiichi Sankyo
5: Pfizer
6: Novartis
7: Bayer
8: Takeda
9: Boehringer Ingelheim
10: Astellas
11: Actelion
12: Johnson & Johnson
13: Shionogi
14: United Therapeutics
15: Bristol-Myers Squibb
16: Gilead Sciences
17: Otsuka
18: Roche
19: Lilly
20: The Medicines Company
Metabolic revenue 2014
1: Novo Nordisk
2: Sanofi
3: Merck & Co.
4: Lilly
5: AstraZeneca
6: Takeda
7: Novartis
8: Amgen
9: Bayer
10: Merck KGaA
11: Salix Pharmaceuticals
12: AbbVie
13: Dainippon Sumitomo Pharma
14: Kyowa Hakko Kirin
15: Mitsubishi Tanabe
Biologic revenue 2014
1: Roche
2: Amgen
3: Novo Nordisk
4: AbbVie
5: Sanofi
6: Johnson & Johnson
7: Pfizer
8: Merck & Co.
9: Lilly
10: Biogen Idec
11: Merck KGaA
12: GlaxoSmithKline
13: Bristol-Myers Squibb
14: Novartis
15: Bayer

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

How to find pharma content that inspires your audience
Getting your customers’ attention begins with presenting pharma content that speaks to their needs and wants effectively....
Bowel Cancer Awareness Month
Synergy Vision are supporting Bowel Cancer Awareness Month. Bowel cancer is one of most common cancers diagnosed in the UK, but with early diagnosis and treatment, most cases can be...
Anthill_icon_Green_18_Dialogue.png
The right way to capture customer data
Digital communication should be a two-way process with information flowing backwards and forwards between you and healthcare professionals. That digital technology enables HCPs to give feedback is a big part...

Infographics